BidaskClub upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research report report published on Friday morning.
Several other brokerages have also weighed in on RGEN. Citigroup initiated coverage on Repligen in a research report on Friday, December 8th. They issued a buy rating and a $45.00 target price on the stock. JPMorgan Chase & Co. started coverage on Repligen in a research note on Tuesday, December 5th. They set an overweight rating and a $42.00 price target for the company. Zacks Investment Research downgraded Repligen from a buy rating to a hold rating in a research note on Wednesday, January 24th. CL King started coverage on Repligen in a research note on Monday, November 13th. They set a buy rating and a $41.00 price target for the company. Finally, TheStreet downgraded Repligen from a b- rating to a c rating in a research note on Monday, November 13th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $44.38.
Repligen (NASDAQ RGEN) opened at $37.01 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.63 and a quick ratio of 8.08. Repligen has a 52-week low of $29.56 and a 52-week high of $46.81. The firm has a market capitalization of $1,620.00, a PE ratio of 74.02, a price-to-earnings-growth ratio of 2.51 and a beta of 0.94.
In other news, Director Thomas F. Ryan, Jr. sold 4,696 shares of the company’s stock in a transaction dated Thursday, March 8th. The stock was sold at an average price of $36.16, for a total transaction of $169,807.36. Following the completion of the sale, the director now owns 9,700 shares in the company, valued at approximately $350,752. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 8,970 shares of the company’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $35.95, for a total value of $322,471.50. Following the sale, the chief executive officer now owns 83,613 shares of the company’s stock, valued at approximately $3,005,887.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,395 shares of company stock valued at $942,122. 1.50% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC boosted its stake in Repligen by 2.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 36,735 shares of the biotechnology company’s stock valued at $1,522,000 after purchasing an additional 1,048 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Repligen by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,402 shares of the biotechnology company’s stock valued at $1,095,000 after purchasing an additional 106 shares during the period. Nationwide Fund Advisors boosted its stake in Repligen by 2.4% during the 3rd quarter. Nationwide Fund Advisors now owns 84,480 shares of the biotechnology company’s stock valued at $3,237,000 after purchasing an additional 1,979 shares during the period. First Trust Advisors LP boosted its stake in Repligen by 20.2% during the 3rd quarter. First Trust Advisors LP now owns 46,910 shares of the biotechnology company’s stock valued at $1,798,000 after purchasing an additional 7,874 shares during the period. Finally, Crossmark Global Holdings Inc. bought a new stake in Repligen during the 3rd quarter valued at approximately $241,000. Institutional investors own 87.60% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first reported by Markets Daily and is the property of of Markets Daily. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.themarketsdaily.com/2018/03/13/repligen-rgen-rating-increased-to-hold-at-bidaskclub.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.